IN THE NEWS
Mayne Pharma Announces Strategic investment in US Facilities
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals. Mayne Pharma provides contract development and manufacturing services to more than 100 clients worldwide...
Mayne Pharma has enhanced its generic products portfolio with 42 products acquired from Teva/Allergan. We now offer branded and generic drugs for a range of therapeutic areas, including oral contraception, oncology, dermatology and cardiology, in an array of dosage forms...
NEWS AND EVENTS
Mayne Pharma Investor Day 2017 1st May, 2017 Investor Day. Live stream will begin at 2.00pm AEST. Mayne Pharma appoints new Group CFO and Company Secretary Mayne Pharma acquires rights to generic Duragesic in the US License and supply agreement for generic Nuvaring in the US
One of the keys to Mayne Pharma’s success has been the implementation of strategic partnerships and alliances by licensing products that we are able to market in the USA or Australia and to develop partnerships for the global marketing of products developed by Mayne Pharma...
Mayne Pharma has a 30-year track record of innovation and success developing new oral drug delivery systems and these technologies have been successfully commercialized in numerous products that have been marketed around the world...
|Market Cap:||52 Week: -|